Lymphoma
Research
Trust
Registered as The Ccpoperative Clinical Cancer Therapy Trust Fund
Charrty Registration No. 263424
Report and Accounts
For the year ended 31 March 2022

Conlonts
1. Legal and administrative informath
2. Structure, governan￿ and management
3. Objecttves and activities
4. Achievements and perf0m￿nCe
5. Financial review
6. Plans for fvIU￿ peri￿Js
7. Statement of Twstees. reSp￿sibIli￿eS
8. Independent examiner's report
9. Slalement of financial aCtivit￿S
10. Balance sheet
11. Notes io the financial statements

Lymphoma Research Trust
{Registered as The Co-operative Clinical Cancer Therapy Trust Fund)
l. Legal and administrative information
Name of the charity
The full name of the Lymphoma Research Trtjsl is The Cl￿peratiVe Clinical Cancer Therapy Tnlst Fund. The
Lymphoma Research Tnjst is registered with the Charity Ccrfnmissioners of England and Wales and its
registration number is 263424.
Trusts8S
The Iruslees who held office duriTVJ the year wwe:
Prof. Steve Schey (Chairman
Ms. IAargargt Littlgjohns
Dr. Cathgrine Anderson (Resigned 23td November 20211
Prof. Steve Devereux
Mr. Paul Smith
Or. Christopher McNamara IAppKJinted 17kn May 20221
Dr. Graham Collins (Appointed I7￿ May 2022)
Principal offi¢0
The principal office of Ihe charity is 5th FI￿ East. 250 Euston Road. Lcffldon NW1 2PG.
Advisors
Bankers
Coutts & Co
440 The Strand
London WC2R OQS
Investment managers
CCLA Fund Managers Ltd
Senator House
85 Queen ￿￿t￿la Street
London EC4V 4ET
Independent examiner
Geoffrey Frosl Bsc (Honsl FCA
Blue Spire Limiled
Cawley Priory
South Pallanl
ChichÈst8r
West Suss8x PO19 1 SY
2. Structurn, gov•rnaneè and management
Struciurn of the charity
The Lymphoma Research Trust was Set up as Tho c￿ratIVe Clini￿1 Cancer Therapy Tnjst Fund by Dged
of Trust dated 2 Decgmbgr 1971.
In 1990 the trustees received pemiission from the Charity Commission lo adopl the informal name of the
Lymphoma Research Trust which conveys Ihe main interesl of the charity more accurately than its original and
oificial name.

Lymphoma Research Trust
(Registered as The Cowoperative Cllnlcal Cancer Therapy Trust Fund)
Recruitmen( appolntment and training of Irustses
Under thg terms of its Deed of Trust. the Lymphoma Re5ear¢h Trust must have at least five trustees. New
trustees are appointed by the continuing ITUStees at their meelings. whKh are held at least ￿lce a year. A
majority of the continuing trustees is sufficyent to elect a new truslee.
TTUSle8s are kept up to dale regulady with changes Telating to Charity I￿L$latIon. Confererw organized by
legal, financial and investmgnt professionals are availablo for trustees to attend. The tru51ees dèlegate the day-
to-day operation of th& charity to the administratoK.
Risk manag•mont policy
The tnAsl&es maintain a risk register and actively review risks which the charity faces on an annual basis.
3. Objectives and a¢tlvltles
Th$ princFpal objecbve of the Lymphoma Research Trust is to provKl& funding for the stLHJy an(1 relief of those
suffering from Hodgkin disease, tumours of the lymph glands, leukaemia and sirrkilar or related diseases. In
formulating and applyiThJ these ￿l'ects. Ihe trustees have regard for the guidanGe of thè Charily Commission
on Public Benefit.
Tho Lymphoma Research Trust do8s this by rnaking grants to research proJramme5. In particular. it has
supwrted the work of the Haematoljgy Trials Group. part of the Cancer Trials Centre at University College
London, for many years. The Haefflalology Trials Group is a leading resear¢h centfe which ctsordinates clinical
trials into all tyP8s of lymphoma - H(xlgkin disease and non-Hodgkin tymphoma.
Grnntamaklng policy
The trustee5 Wglcome grant ap￿iCatIonS from centres of excellence for tymphoma research in the UK. Grant
applications are reviewed again51 thè objects of the charity afid Whe￿ rekvant or necessary, the tru$tg8s will
afrange for peer review of applicati￿s.
4. Achievements and ￿rfornIance
The Lymphoma Research Trust ¢ontinues to support the Haematok)gy Trials Group al Universty College
London. In August 2021, £502,956 was grante(I to provKle funding for the group for Ihree ygars from January
2022 to December 2024. This was lo fund a lum(KJr group lead120%1. a data manager1100%1, a senior trials
CO-ordinalor1100%1 and a database deVelO￿r(so%) whith facilitste the rna1ntenan￿ of Ihe trials databases
and trials where a long-lerm as5e5sment of treatmenl eff￿. and treatment rèlated toxictty 15 required. This
gnables them to improve patient care with the development and optimisation of therapy re5ultin9 in a reduclion
in morbidily and mortality. The charity also continued to provide funding for a Lyrnphoma Clinical Trials Fellow.
In August 2021, £67.915 was granted for the iwo years from February 2022 lo January 2024.
The Haematok)gy Trbals Gr(KJP is an aclive research ￿tIVe gmup 4 tymphoma trials open to recruitment
and 7 at the sel-up stage or grant application slage or where patients are being followed up for outcomes to
treatment. In addition to this. ihe group manages a further 9 Irials where resu115 are being written up or presented
al conferences. Further information on trsals can ￿ found on the CR UK and UCL Cancer Trials Centre
website at htt ."Ilwww.clc.ud.ac.uk.
Thè continued support from the Lymphoma Researth Trust has been frjndamenlal in shaping the Haemalology
Trials Group and has helped the group SL￿Ceed in running praclice-changing trials.
During the year. the tnjstees awarded £30.762 lo Dr. OffoT of the Wollson ch1k1h￿)d Cancer Research Centr8
for his project on investsg*ing Epstein Barr Virus immunity in children al high risk of post-transplant
lymphoproliferalive diseases. They also awarded £12.697 lo Dr.Kim Linton of The Christie NHS Foundation
Trust for her projed on CSF microRNA5 a5 FK)tential diagnoslic and prognoslK markers in Primary Central
Nervous System Lymphoma.

Lymphoma Research Trust
(Registered as The cO￿perative Clinical Cancer Therapy Trust Fund)
5. Financial review
Durirtg 2021-22, the Lymphoma Research Trust Tec*ived many donations from patients, their relatives and
friends. Donations amounted to £96.44212021.. £75.380I- Wrtholrt these donation5. Ihe Lymphoma Research
Trust's ability to lund essgntial Core research woukl be seve￿ty curtailed an¢J the trustees are very grateful for
the support of dorsors and fundraisers. The charity received legacies totaling £3,671 during the year12021..
£90.CIXII. Investment Ir￿)me was £42.63712021: £43.4011. This brought income from all sources in the year
to a total 01 £142,750 {2021.' £208,781).
Expenditure on generating lunds vrds £15.YJ8 {2021.. £22,083). A grant for the core support for 3 years was
approved lo the Haematology Trials Group. a5 well as other grants. as dI￿uSSed above. Exper￿lture on
charitable activities was £558,68012021: £2.1501. Totsl expenditure for 2021-22. induding the Core Support
Grant, came to £574.27812021-. £24,233).
R8s•rv8s pollcy
The trustees. policy is to ensure that total assets cover at least three years. estimated costs forthe management
of trials. the cost of one Lymphoma Clinul Fellowship over a thr￿year periol, and the full outstanding costs
of 5pecrfic projects lo which the Iw5tees are committed.
The levgl of funds at 31 March 2022 after d￿l￿ting grant Commrtments already made was £1,045,958
compa￿d with £1,344,236 at 31 March 2021.
Investment policy
The Irustses h8vg widg powers of investment conferred on them by the Deed of Trust.
The Lymphoma Research Trust is invesled in the CCLA COIF Charibes Investment Fund. Th8 trustees re¢eivg
regular reports on Ihe perf0m￿nCe of Iheir investments and the investment managers meet the trustees once
a year.
Given the long-temi nature of the wovk undertaken. the trustees have set an investment strategy for funds.
beyond their iwnmediale day to day requirements. which seeks lo balan￿ ￿rrent irKome with longerterm capital
appreciation in order to seek to preserve the real value of Iheir funds.
The trustees monitor the cash Ilow of the charity dosely.
6. Plans for future periods
Th6 Lymphoma Research Trustwill continue to make grants to StApw)rt research into ￿ causes and Ireatmenls
of lymphoma.
7. Statement of Trustees. responsibilities
The Iruslees are responsible for preparing Ihe Tnjstees. Annual Report and the finanaal statements in
a¢¢ordan¢g with applicable law and United lfj"ngd¢yn A¢counb"ThJ Stsndards (United Kingdoffl Generally
A¢¢epted k¢ounting Practice).
Thg law applicable to charities in England & Wales rgquir8s th8 trustees to prepare financial statgm&nts for
each financial year which give a true and fair view of the slate of affairs of Ihe charity and of the incoming
resources and application of resources ofthe charity for that period. In preparing these financial stalements. the
trustees are required lo..
select suitab￿ ac(x)unling arwj then apply them ujnsistentty:
observe the methods arKI prirKiples in the Charitw SORP;
make judgemerts and eslimale5 that are reasonable and prudent.,

Lymphoma Research Trust
(Registered as The Coryoperatlve Clinical Cancer Therapy Trust Fund)
state whether applicable accounting stan¢Jards have been lollowed. sutry'ect lo any material
departures di￿10$￿ and explained in the finawal statemenls:
prepare the financial statements on the going cJ)rKem basis unless it is inappropriate to
p￿Sum@ that the charity will ¢ontinue in operation.
The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy al
any lime the financial position of the charity and enable Ihem to ensure that the financial statements ¢omply
with the charib.es Act 2011. the Charity IA¢¢ounls and ReFM)rtsl Regulations 2008 and the provisions ol th6
trust deed. They are also re
nsible for safeguarding the assets ofthe charity and hence for taking reasonable
steps for the pfevent.
deledion of fraud and olher irregularities.
Trustees on i loii and sNJned ￿ its behaw by..
Approved by
Piof S. Sche
Chairman

Lymphoma Research Trust
(Registered as The Co-operative Clinical Cancer Therapy Trust Fund)
8. Independent Examinerfs Report to the Trustees of Lymphoma Re5ear¢h Trust
l report to the charity Iru51ee5 on my eXaminab.￿ of the a¢u)unts of the charity for Ihe year ended 31 March
2022.
Re$ponsibllltles and basis of rnport
As the charity's trustees you are responsible for the preparation of the ac￿Unts in accordance with the
requirgments ol Ihe Charities Act 2011 I'the ACY).
I report in respect of my examination of the Charity's a¢¢ounts Cal￿d out under section 145 of Ihe Act and in
carrying out my examinalion I have followed all the ap￿IcAble Direcbons given by Ihe Charity Commission under
section 14515llbl of the Act.
Independont examlnèrfs stat8menl
I have completed my examination. l u)nfirm that material matters have come to my attention in conne¢tion
with the exarnination giving me cause to Wieve that in any material rgsKWt:
acu)unting records w8r8 not kept in respect of Ihe charity as required ty section 130 of the Act.. or
the accounts do nol accord with those records; or
thè accounts do nol comply with Ihe applicable requwements o)ncerning the form and content of accounts
set out in the Charities (Accounts arid ReFK)rtsl RegulalKJns 2(X)8 other than any requirement that thè
accounts give a Yrue and fair view. whi¢h 1$ nota mattw ¢onsKJered as part ol an independent examinatson.
I have no concerns and havecome across no other matters in connection with the examination to which attention
should be drawn in this report in order to enabk a prO￿r understanding of the accounts to be reached.
10 November 2022
Geoffrey Frost BSclHonsl FCA
Blue Spire Limited
Cawley Priory
South Pallant
Chichester
West Sussex
P019 1SY
Dale

Lymphoma Research Trust 2021-22
9. Statement of Financial Activities for the year ended 31 March 2022
Unrestricted Funds
Notes
2022
2021
Income and endowments from:
Donations
Legacies
Investments
Total
96,442
3.671
42.637
142.750
75.380
90.000
43,401
208,781
Expenditure:
Raising funds - investment management costs
Raising funds - fundraising costs
Charitable aciivities
Total
9,140
6.458
558,680
574.278
8.674
13,409
2,150
24,233
Net gainsl(losses) on investments
133,250
262.542
Not incomel{expenditure)
(298,278)
447.090
Fund balances brought forward at 31 March 2021
1.344,236
897,146
Fund balances carried forward at 31 March 2022
1045 958
1344 236

Lymphoma Research Trust 2021-22
10. Balance sheet as at 31 March 2022
Unrestrlcled Funds
2022
2021
Fixgd a$s¢ts
Invèstments
1.$06,$03
1.482,393
Current assèts
Debttsrs.. prepayments and irtc4ne
Cash at bank and in harKI
Total eurr•nt ass•ts
92,585
170.131
262,716
99,214
132.169
231,383
Currènt liabllitl•s
Accruals
{8001
{29,5361
1343,8131
1374.1491
{7001
{39,S751
1240,9871
1281,2621
Other creditors
Grants payable
Totsl eurr•nt Ilabllltl•s
Nèt eurr•nt ass•ts
1111.4331
149,8791
Totsl as￿1$ ￿$$ curr•nt Ilabllttl•s
1.395.070
1.432,514
Crediiors.. amounls falliThJ due after one year
1349,1121
{88,2781
Net asset
1.045.958
1.344236
Accumulated funds
Brought forward at 31 March 2021
Surpluslldeficill for the year
1.344.236
1298.2781
897.146
447,090
Total funds
1,04S,958
1,344,236
The notgs numbér￿ 1 to 7 fo
pa
of these ￿t￿nts.
Approve(I by the Bo8ril
and sw)ned on its ￿half by."
Chaimia

Lymphoma Research Trust 2021-22
11. Notes to the Financial Statements
A¢¢ountlng policies
1.1 A¢counting convention
The Lymphoma Research Tmst is an unirwrporated charity regislered in England governed by a
constitulion. The address of the principal Offi￿ is 5th Floor East. 250 Euston Road. London, NWI
2PG and the tharitls operab.ons and prinopal acbvities are sel out in the trustees. report.
The charity con51itules a KAJblic benefit entrty as defined by FRS 102. The financial ststements
have been prepared in accordan￿ with Accounting 8nd Re[K)￿n9 by Charities.. Statement of
Recommended Practice aP￿1¢able to tharities preparing their accounts in accordan￿ with the
Financial Reporting Slandard appIl￿ble in the UK and Republic of Ireland issued in October
2019, the Fin8n¢ial Reporting Slandar(l appIl￿ble in the United Kingdom and RewJbli¢ of Ireland
IFRS 1021, the Charities Act 2011 and UK Generally A(￿pIed Practi￿.
The financial slalements are wepared on a wing COn￿M basis under the historical cost
convention. modified lo indude certain item5 al fair value. The financial statements are presented
in sterling which is the fun¢thonal currency of the charity 8nd rounded to the nearesl £.
1.2 statement of ¢ash flows
The charity does not indude a wh flow statement M the grounds that it is applying FRS 102
Section 1A.
1.3 Incomo r8cognition
All incoming resou￿$ are induded in the stste￿nI of Finanaal Activities {SoFAI when the
charity is legally entiued lo the income after any perf0mlan￿ conditions have been met, the
amount can be measured reliably and it is wobable that the income will be received.
Investment income is earned through hol¢Jing assets for investment purposes such as shares. It
includes dividends and Trnterest. Where it is not practi¢8ble lo identify investment management
costs tncurred within a scheme with reasonable accuracy the investment income is reported net of
these Costs. It is included when Ihe amount can be measured reli8bly. Interesl income is
recognised using the effective interest method and dividend and rent income is recognised as the
charity's right to re￿1ve payTnenl is established.
1.4 Rocognition of expendlturo
l expendrture is accounted for on an ac(xuals basis and has been das5ifie(l under headings that
aggregate all costs related lo the category. Expendilure is recognised where there is 8 legal or
construclive obligation to make payments to third parbes. il is probable thal Ihe settlement will be
reqUI￿d and the amount of the obligabon can be measured reliably. It is categorised under
expenditure on tharilable activities and indudes upkeep of Ihe charivs propeities and the cosl of
administering the activity of the charity.
Support cosls are those that assist the work of the charity but do not diwlly represent charitable
activities and indude office costs. and g0Veman￿ cosls. They are incurred diredy in support of
expenditure on the objects of the charity and on raising funds for the charity. Support costs are
allocated to expenditure on tharilable ach"vibes and raising funds on a basis consistent with the
use of those funds.

Lymphoma Research Trust 2021-22
11. Notes to the Flnanclal SL￿eMents
Accounting policies
1.5 Cash & cash eqvivalonts
Cash & cash equivalents indudes cash at bank and in hand and cash held within the investment
portfdio.
1.6 VAT
The charity is not registered for VAT 8nd is unable to recover VAT Ir￿u1r&I. On this basis costs
are recorded inclusive of VAT within the SOF
1.7 Ftx8d asset inveslments
Investments are recognised inilially at farr value which is nom)ally the transa¢tson price excluding
transaction costs. Subsequenuy. they a￿ measu￿d 8t fair value with Changes recognised in 'nel
gains I Ilossesl on inveslmenls. in the SOFA where investrnents are publidy traded or their fair
value can otherwise be measured r￿la￿y.
1.8 Debtors receivable and Creditors payable within one year
Debtors and ¢xe(litors with no stste(l Énlerest rale and r￿1vab￿ CY payable within one year are
recorded at transackn.on price. Any105se5 arising from impairment are recognised in expenditure.
1.9 Taxation
The charity is consmlered to pass the tests set oul in secaions 521 to 536 Income Tax Acl 2007
IITA 20071. as such no income tax is payable ￿ Ihe charitys activibes.
1.10 Going concgrn
The financial statements have been prepared on a going ¢x)ncem baws as the trustees believe
that no m81erial uncertainties exist. The trustees have ￿nSIdered Ihe level of funds held and the
expected level of income and expenditure for 12 months from authorising these financial
statements. The budgeted income and expendilure is sufficient with Ihe level of reserves ft)r the
charity to be able to ￿ntinue as a going ¢on(wn.

Lymphoma Research Trust 2021-22
11. Notes to the Flnancial SLitements {¢ontlnu•d)
knalysi$ of charIta￿e oxp8ndilw*
2021-22
202041
Grants to Instiluti(xi$'.
LyThphorna dini(*l lria8 le
Core SUp￿rt (C￿cer Research UIWCL Tri* Centrel
Dr. Ugo or[￿. UnN. NO￿aS￿e
K Linton- ChriS￿"e NHS FourKlolKm Tntst
SukV)rt wsts IrK)le 31
Grant ￿te back5
67.915
30.762
12.697
2.281
157.9311
2,150
2.150
Allocatlon of support ¢¢)sts
Totsl
support
Ral￿Thj
Exper¥Jiivie ty￿..
sialf (xJsts
rin* spent on xli￿lieS
Independ8nt eXarnInatN￿ fees Prormyt￿I to stalf costs
Other
5.000
541
219
2.158
5.637
2,281
7,918
Flx¢d asset Inv051rnents
2021
Movomoni$ in lhe
Market valu8 at 1 2021
Add" Acquisilions at cost
L855.' Disp05als atrarrwThJ value
Unreaised Ik)ssesygairts
Market value a131 Marth 2022
1.482,393
1A95,79S
11.482,3931
10.708
1.S06.503
1.228.525
253,868
1,482,393
H￿ori¢ (XX8t
1.495.795
1.250.000
Investm8nts cLYiw:
CCLA Mar￿30d fund5
1.506.$03
1.482.393
2021
Invtslment Incorno
thvidend inc(m
Bank d8F#)sil inlwest
42.584
53
42,637
43.133
43.401
IAdep8ndent examinerf$ r¢munerallon
(kn18rnance c0515 indude an arrK4ml 01 £660 pJyJJe to the iTh*end8nl examiner la)21: £8(X>l for an
Tru$taes' remuneTrlion and r¢lated party transaction5
The trustees receiv￿1 r&7M*xration thJrirvJ the yw12021: EOI. Tr￿1 eXFW￿5 01 £21 reift*KJrsed
to IrL￿tee$l202].. £01.

Lymphoma Research Trust 2021-22
11. Notes to Ihe Flnanclal Statements (continued)
Financial instrum•nts
The amounts of Ihe charitys financial instrurnents are as lob1¢)￿..
2022
2021
Financial a&￿ts
Measured at fair value thrrwh n8t inc0N*l{expendthJ￿)'.
Fixed asset inveslrnents
1.506.503
1,482,393
The ir￿me, expense. net gains and ret kjsses atlributatAe to the charitys financial instruments are
sumrnarisgd as foliiy•ts.'
2022
2021
Income and expense
Financial assets measured at lair value Ihrough rel incrThllexpendrturel
Investment income
Investment man8g8rnent fees
42,584
19,1401
33,444
43.133
18.6741
34,459
2022
2021
Net gains al￿ Ioss85 lindudiThJ changes In fair Yaluel
Financial assets rrea$ured at fair value thrwjh nel iwThl{expenditurel
Nel gainslllossesl inves1m￿S
133,250
262,542
Fixed asset investments a￿ held at fair v8lue with valuab.ons obtained by reference to market pri￿$ Irorn the
appropriate stc*k exChar￿e. bid Pri￿ and last trad￿1 prices where applicable.